Netherlands· NL-863ec973e7db

Tolvon, tabletten 10 mg

A mianserin product containing mianserinehydrochloride, registered in Netherlands by N.V. Organon (Kloosterstraat 6). The same ATC class is registered in 15 of our 19 countries.

ATC N06AX03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about mianserinehydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Mianserin is registered in 15 of 19 countries.

Countries holding a registration under ATC N06AX03 (mianserin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search mianserin products by name

Mianserin · ATC N06AX03

15 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mianserin costs, country by country.

Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.32 in France to $1.15 in Switzerland — a ×3.6 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Mianserin · price per daily dose (60 mg)

USD · FX 28 Sept 2026

CH Switzerland$1.15
IT Italy$0.68
FR France$0.32

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: MIANSERINEHYDROCHLORIDE
Manufacturer: N.V. Organon (Kloosterstraat 6)
Country: Netherlands (NL)
ATC code: N06AX03
ATC class: Mianserin
Defined daily dose: 60 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
09041

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

19 interactions on record for mianserin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check mianserin against other medicines How interaction checks work

Mianserin · interactions on record

19 records

19 more interactions with mechanism and management, from a commercially licensed source.

Mechanism and what to do, in the interaction check

Interaction register. Grades as the source publishes them.

Same medicine, other countries

Mianserin in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mianserin products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

Austria · Mianserin Viatris, Tolvon
Belgium · Lerivon
Cyprus · Mianserin Remedica
Czechia · Lerivon
Germany · Mianserin, Mianserin Neuraxpharm
Denmark · Mianserin Orifarm, Mianserin Viatris
Spain · Lantanon
Finland · Tolvon
France · Mianserine Arrow, Mianserine Biogaran
United Kingdom (Northern Ireland) · Mianserin Generics Uk
Hungary · Miagen
Iceland · Mianserin Mylan
Italy · Lantanon
Luxembourg · Lerivon
Malta · Mianserin Remedica
Norway · Mianserin Viatris
Poland · Deprexolet, Lerivon
Portugal · Tolvon
Sweden · Mianserin Viatris
Slovakia · Lerivon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/57b8ff5a-b96a-4e1b-b0f5-dd655574ec29
GET /v1/drugs/57b8ff5a-b96a-4e1b-b0f5-dd655574ec29?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h09041_smpc.pdf",
  "strength": null,
  "atc_label": "Mianserin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg09041",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 2-WATER (E 341)",
    "HYPROMELLOSE (E 464)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "METHYLCELLULOSE (E 461)",
    "POTATO STARCH (RI)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "MIANSERINEHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h09041.pdf",
  "authorised_at": "1981/10/07",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "09041",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about mianserin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console